# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $...
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.42) per share which met the analyst consensus estimate. ...
Allegheny Health Network (AHN) Cancer Institute has become the first health care system in Western Pennsylvania to offer a firs...